Truist Securities Maintains Buy on Insmed, Lowers Price Target to $85
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Nicole Germino maintains a Buy rating on Insmed (NASDAQ:INSM) but lowers the price target from $88 to $85.
August 12, 2024 | 1:10 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities maintains a Buy rating on Insmed but lowers the price target from $88 to $85.
The maintained Buy rating is positive, but the lowered price target may indicate tempered expectations. The overall impact is neutral as the positive rating balances the slight reduction in price target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100